MX:BMRN Stock Latest News

BioMarin ends VOXZOGO development for Noonan syndrome

PremiumCompany Announcements

6h ago

BioMarin to discontinue development of Voxzogo for children with Noonan syndrome

PremiumThe Fly

7h ago

BioMarin Pharmaceutical Adds Independent Director to Board

PremiumCompany Announcements

1d ago

BioMarin names Robert Plenge, M.D., Ph.D., to board of directors

PremiumThe Fly

1d ago

BMY

BioMarin: Neutral (Hold) Rating Reiterated as VOXZOGO Opportunity Balances YUVIWEL Competitive Risk; $60 Price Target Unchanged

PremiumRatingsBioMarin: Neutral (Hold) Rating Reiterated as VOXZOGO Opportunity Balances YUVIWEL Competitive Risk; $60 Price Target Unchanged

5d ago

BioMarin reports new data from Phase 3 CANOPY-HCH-3 study

The Fly

BioMarin reports new data from Phase 3 CANOPY-HCH-3 study

6d ago

Ascendis Pharma price target raised to $312 from $304 at Oppenheimer

The Fly

Ascendis Pharma price target raised to $312 from $304 at Oppenheimer

13d ago

BioMarin Completes Acquisition of Dutch Biotech Alesta Therapeutics

PremiumCompany Announcements

14d ago

BioMarin completes agreement to acquire Alesta Therapeutics

PremiumThe Fly

14d ago

Balanced Upside and Execution Risks Lead Richter to Maintain Hold on BioMarin After ASND Settlement and Voxzogo Expansion Plans

PremiumRatings

14d ago

BioMarin Settlement with Ascendis Clears Legal Overhang; Analyst Reaffirms Buy Rating and Maintains $114 Price Target

PremiumRatings

14d ago

PremiumThe FlyBioMarin price target raised to $86 from $85 at Cantor Fitzgerald

14d ago

Ascendis Pharma price target lowered to $273 from $275 at Morgan Stanley

The Fly

Ascendis Pharma price target lowered to $273 from $275 at Morgan Stanley

14d ago

BioMarin price target raised to $90 from $88 at Piper Sandler

The Fly

BioMarin price target raised to $90 from $88 at Piper Sandler

14d ago

BioMarin Kept at Hold as YUVIWEL Royalties Lift DCF and Price Target Rises from $59 to $60 Amid VOXZOGO Headwinds

PremiumRatings

15d ago

Analyst Sees BioMarin Undervalued After Ascendis Settlement, Modestly Raising Price Target to $105

PremiumRatings

15d ago

H.C. Wainwright trims Ascendis target, says litigation overhang removed

PremiumThe Fly

15d ago

BioMarin price target raised to $105 from $104 at Jefferies

PremiumThe Fly

15d ago

PremiumThe FlyBioMarin price target raised to $60 from $59 at H.C. Wainwright

15d ago

BioMarin price target raised to $109 from $105 at Raymond James

The Fly

BioMarin price target raised to $109 from $105 at Raymond James

15d ago

Ascendis Pharma price target lowered to $304 from $306 at BofA

The Fly

Ascendis Pharma price target lowered to $304 from $306 at BofA

15d ago